ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
21.01
-0.42 (-1.96%)
Mar 30, 2026, 4:00 PM EDT - Market closed
ArriVent BioPharma Employees
ArriVent BioPharma had 77 employees as of December 31, 2025. The number of employees increased by 25 or 48.08% compared to the previous year.
Employees
77
Change (1Y)
25
Growth (1Y)
48.08%
Revenue / Employee
n/a
Profits / Employee
-$2,159,844
Market Cap
928.68M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 77 | 25 | 48.08% |
| Dec 31, 2024 | 52 | 12 | 30.00% |
| Dec 31, 2023 | 40 | - | - |
| Sep 30, 2023 | 42 | - | - |
| Jun 30, 2023 | 40 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,300 |
| AbCellera Biologics | 562 |
| Xeris Biopharma Holdings | 435 |
| KalVista Pharmaceuticals | 275 |
| Geron | 258 |
| uniQure | 221 |
| EyePoint | 214 |
| Zenas BioPharma | 167 |
AVBP News
- 6 days ago - ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib - Seeking Alpha
- 13 days ago - ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting - GlobeNewsWire
- 25 days ago - ArriVent BioPharma Reports Full Year 2025 Financial Results - GlobeNewsWire
- 3 months ago - ArriVent BioPharma: Its Leading Asset Furmonertinib Supports A Cautious Buy - Seeking Alpha
- 3 months ago - ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts - Seeking Alpha
- 3 months ago - ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer - GlobeNewsWire
- 5 months ago - ArriVent BioPharma Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 6 months ago - ArriVent Appoints Brent S. Rice as Chief Commercial Officer - GlobeNewsWire